Tags : GE Healthcare

Top 20

Top 20 Diagnostics Companies Based on 2020 Revenue

The extraordinary demand for COVID-19 testing kits that were seen in 2020 and is yet to subside in 2021 resulted in many of the world’s biggest diagnostics companies being thrust into the limelight Siemens Healthineers, GE Healthcare, Roche, and Abbott are the top players in the race of the global diagnostic companies. The companies are […]Read More

Top 20

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics […]Read More

Top 20

Top 20 Medical Device Companies Based on 2019 Revenue

The Medical device market is growing with evolving needs of patients and with their emerging diseases encouraging them to develop novel and innovative therapies or devices for maintaining quality of life. The ledger for 2019 of medical devices has shown changes for multiple companies but the position for Medtronic remains same to be one top […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 13 -17, 2020)

1. Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19 Published: Apr 17, 2020 | Tags: Sinovac, Initiates, P-I, Clinical Study, Vaccine Candidate, Against, COVID-19 2. 1Health.io Launches Self-Collection Kits to Detect COVID-19 Published: Apr 16, 2020 | Tags: 1Health.io, Launches, Self-Collection Kits, Detect, COVID-19 3. Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations […]Read More

COVID-19 DigiHealth

GE Healthcare and Microsoft Exploit Remote Patient Data Monitoring Technology

Shots: The company launches Mural Virtual Care Solution, which allows clinicians to view numerous ventilated patients simultaneously and remotely and enables early identification of patients at risk of deterioration The Mural Virtual Care utilizes Microsoft Azure that enables the management and surveillance of ventilated patients at scale. The launch of Mural is the latest step […]Read More


PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 02-06, 2019)

1.  Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders  2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More


GE Healthcare Signs an Agreement with Affidea to Deploy Digital

Shots: GE Healthcare will install 200+ new equipment including 60 new MRIs, 50 ultrasound devices, 40 CT scanners, and 30 X-rays machines in the next 3 yrs. in Affidea’s network of centers across EU and will pay $100M to Affidea Additionally, Affidea expands its collaboration with GE Healthcare in pharmaceutical diagnostics in all its geographies, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (October 07-11, 2019)

OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid Antigen Test, Orasure Technologies, Rapid, Receives, The US FDA, Marketing, Approval, Detection, Ebola Virus Antigens 2. Alnylam Reports Submission of MAA to Brazilian Health Regulatory […]Read More


GE Healthcare Signs a Worldwide Development and Commercialization Agreement with

Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer   The companies […]Read More